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In order to identify acute myeloid leukemia (AML) CD34
þ -specific gene expression profiles, mononuclear cells from AML patients (n ¼ 46) were sorted into CD34 þ and CD34 À subfractions, and genome-wide expression analysis was performed using Illumina BeadChip Arrays. AML CD34 þ and CD34 À gene expression was compared with a large group of normal CD34 þ bone marrow (BM) cells (n ¼ 31). Unsupervised hierarchical clustering analysis showed that CD34 þ AML samples belonged to a distinct cluster compared with normal BM and that in 61% of the cases the AML CD34 þ transcriptome did not cluster together with the paired CD34 À transcriptome. The top 50 of AML CD34
þ -specific genes was selected by comparing the AML CD34
þ transcriptome with the AML CD34 À and CD34 þ normal BM transcriptomes. Interestingly, for three of these genes, that is, ankyrin repeat domain 28 (ANKRD28), guanine nucleotide binding protein, alpha 15 (GNA15) and UDP-glucose pyrophosphorylase 2 (UGP2), a high transcript level was associated with a significant poorer overall survival (OS) in two independent cohorts (n ¼ 163 and n ¼ 218) of normal karyotype AML. Importantly, the prognostic value of the continuous transcript levels of ANKRD28 (OS hazard ratio (HR): 1.32, P ¼ 0.008), GNA15 (OS HR: 1.22, P ¼ 0.033) and UGP2 (OS HR: 1.86, P ¼ 0.009) was shown to be independent from the well-known risk factors FLT3-ITD, NPM1c þ and CEBPA mutation status.
Introduction
Acute myeloid leukemia (AML) is clinically, cytogenetically and molecularly a heterogeneous disease, which makes it challenging to classify it properly. Currently, patients diagnosed with AML are stratified into separate risk groups based on morphological, cytogenetic and molecular abnormalities. 1, 2 However, especially in the intermediate risk group that represents the largest AML subgroup (60%), treatment outcome varies considerably. Within the intermediate risk group, subgroups are recognized based on mutations in the nucleophosmin 1 (NPM1) (leading to cytoplasmic dislocalization of NPM1 (NPM1c þ )) and fms-related tyrosine kinase 3 (FLT3) genes or based on biallelic mutations in the CEBP a gene. [3] [4] [5] Identification of novel molecular markers might therefore be helpful for further risk stratification. In recent years, a number of gene expression profiling (GEP) studies has been performed in order to improve the identification of known cytogenetic subgroups and to recognize new clusters of AML patients with distinct gene-expression signatures. [6] [7] [8] [9] [10] [11] Most of these AML GEP studies have been performed using the total AML-mononuclear cell (MNC) fraction. [6] [7] [8] [9] As cell lineage and differentiation stages affect gene expression-based clustering, 6, 7, 10 the differentially expressed genes associated with the differentiation stage might obscure more basic gene expression information related to tumor initiation and maintenance. Consequently, profiling of a more homogenous leukemic cell population, instead of the total MNC fraction, might enhance the feasibility of using GEP to identify novel prognostic markers.
AML is thought to be initiated and maintained by relatively small numbers of leukemia-initiating cells that have an enhanced self-renewal capacity and can engraft in immunodeficient mice. 12, 13 In the vast majority of leukemias, leukemiainitiating cells have been found to reside in the CD34 þ compartment. [12] [13] [14] [15] [16] [17] Studies aimed at further enrichment of leukemia-initiating cells revealed substantial heterogeneity in cell surface marker expression, [18] [19] [20] [21] [22] [23] and it has been observed that leukemia-initiating cells can reside both in the CD34 þ / CD38 À and in the CD34 þ /CD38 þ fractions. 24 In our current study, AML-MNC fractions were sorted in CD34 þ and CD34 À subfractions and gene expression was compared with a large group of normal CD34 þ bone marrow (BM) cells. Thus, we were able to identify AML CD34 þ -specific gene expression profiles, which included a number of genes that could significantly predict prognosis in normal-karyotype AML independent of already established prognostic factors.
Materials and methods

Patient material
GEP was performed on blast cells of 46 patients with AML from a single center (University Medical Center Groningen).
The diagnosis of AML was based on cytological examination, immunophenotyping and cytogenetic analysis of blood and BM. AML blasts were collected from peripheral blood (PB) or BM (n ¼ 7) after achieving informed consent. For 3 out of 46 patients, cells from relapsing disease were used and one AML was preceded by a myelodysplastic syndrome. The study was approved by the Medical Ethical Committee of the UMCG. MNCs were isolated by density gradient centrifugation using lymphoprep (PAA, Cö lbe, Germany) and cryopreserved. After thawing, CD34 þ and CD34 À AML cells were selected by MoFLo sorting (Dako Cytomation, Carpinteria, CA, USA) using a CD34 PE-labeled antibody (Clone 8G12, BD Biosciences, San Jose, CA, USA). Cytogenetic risk group distinction (favorable, intermediate, and unfavorable) according to current HOVON/SAKK protocols is provided in Table 1 . [25] [26] [27] Potential donors for allogeneic BM transplantation and patients who underwent elective total hip replacement served as normal controls (n ¼ 31) after providing informed consent. From the normal BM aspirates the MNC fraction was isolated and CD34-enriched fractions were obtained using anti-CD34 magnetic beads (Clone QBEND/10, Miltenyi Biotec, Auburn, CA, USA). We realize that differences in procedures that were used to isolate CD34 þ cells from NBM and AML samples may have resulted in some changes at the transcriptome level. Nevertheless, we currently do not have indications that different CD34 þ populations were obtained via these methods as different antibodies were used, or that these potential differences in transcriptomes were main determinants in our clustering analyses.
Analysis of mutations in NPM1 and FLT3
Detection of NPM1 mutations was performed by immunohistochemical staining on BM biopsies that were fixed in 10% neutral phosphate buffered formalin (3.6% formaldehyde) for at least 12 h, and decalcified in a solution containing 10% (v/v) acetic acid and 10% formalin (v/v; 3.6% formaldehyde) for 1 or 2 days. Detection of NPM1 localization was performed on paraffin embedded 3 mm tissue sections by immunohistochemical staining using a Benchmark XT (Ventana Medical Systems S.A., Tucson, AZ, USA). The antigens were retrieved with EDTA buffer (pH 8.5) and endogenous peroxidase was blocked with H 2 O 2 . Slides were incubated with 1:50 diluted supernatant of the biotinylated anti-NPM1 antibody (kindly provided by Prof. Falini, Perugia, Italy). Antigens were visualized using the ultraview universal DAB detection kit (Ventana). Exclusive nuclear versus a combined nuclear and cytoplasmic localization of the protein was scored by an experienced hematopathologist. The sensitivity and specificity of the assay have been tested on a series of more than 100 AML also analyzed for mutations in the NPM1 gene.
Mutational analysis of ITD within the JM domain of the FLT3 gene was performed with RT-PCR using primers 5 0 -CAATTT AGGTATGAAAGCC-3 0 and 5 0 -CAAACTCTAAATTTTCTCT-3 0 , as previously described. 28 
Gene expression profiling
Total RNA was isolated using the RNeasy mini kit from Qiagen (Venlo, The Netherlands) according to the manufacturer's recommendations. RNA quality was examined using the Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany). Genome-wide expression analysis was performed on Illumina (Illumina, Inc., San Diego, CA, USA) BeadChip Arrays Sentrix Human-6 (46k probesets). Typically, 0.5-1 mg of mRNA was used in labeling reactions and hybridization with the arrays was performed according to the manufacturer's instructions.
The RMA method in R version 2.4.0 (http://www.r-project.org) was used to compute probe sets summaries. 29 Quantile normalization was applied to log 2 -transformed intensities. 30 Principal component analysis was performed for quality control. [31] [32] [33] [34] The MIAME-compliant microarray data are available at http:// www.ncbi.nlm.nih.gov/geo/ under accession number GSE30029.
To perform further analyses two publicly available cytogenetically normal AML data sets (GSE16891 (NCBI GEO); n ¼ 218) 6, 35 and (GSE12417 (NCBI GEO); n ¼ 163) 36 were utilized. The selected data sets provided us with clinically annotated gene expression values from Affymetrix Human Genome U133A or U95 gene chip array (Affymetrix, Santa Clara, CA, USA). 9 /l at diagnosis, or inv(16)/t(16;16) and no unfavorable cytogenetic abn.; unfavorable risk: inv(3) or t(3;3), t(6;9), t(v;11)(v;q23) other than t(9;11), À5 or del(5q), À7, abn(17p), complex karyotype (three or more abnormalities in the absence of a WHO designated recurring chromosome abnormality); intermediate risk: all chromosome abnormalities not classified as favorable or unfavorable.
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Class comparison
Class comparison was performed using the software package Biometric Research Branch ArrayTools (BRB ArrayTools) version 3.6.0, developed by the Biometric Research Branch of the US National Cancer Institute (http://linus.nci.nih.gov/BRB-ArrayTools.html). As the CD34 þ and CD34 À AML samples were paired samples (n ¼ 44), a paired t-test was used to identify differentially expressed genes. For the comparison CD34
þ NBM (n ¼ 31) a random variance t-test was used. Differential expression was considered significant at Po 0.0001. Average linkage hierarchical clustering with the centered correlation distance metric was performed using Cluster 3.0 and TreeView software (http://www.eisenlab.org/eisen/). 37 
Statistical analyses
Statistical analyses were performed with SPSS software (IBM, Amsterdam, The Netherlands), release 16.0. Actuarial probabilities of overall survival (OS) (with death due to any cause) as well as event-free survival ((EFS), with failure in case of no complete remission or relapse or death)) were estimated according to the Kaplan-Meier method. Overall group differences were evaluated using a Mann-Whitney U test, w 2 -test or Fisher exact in 2 Â 2 setting. Correlations were calculated with the Spearman's rank correlation coefficient (r). The association between transcript levels of the top 50 CD34 þ AML specific genes and OS, and EFS was tested in univariate Cox models. Multivariate cox regression analysis was applied to determine the association of ankyrin repeat domain 28 (ANKRD28), guanine nucleotide binding protein, alpha 15 (GNA15) and UDP-glucose pyrophosphorylase 2 (UGP2), and OS/EFS with adjustment for known disease-related risk factors, such as FLT3-ITD, NPM1c þ and CEBPA mutations. Of note, when multiple probe sets representing the same gene were present on the Affymetrix arrays, probes were averaged. All tests were two tailed, and a Po0.05 was considered statistically significant.
Results
Samples were available from 46 AML patients, of which 44 were paired CD34 þ and CD34 À samples. Patient characteristics are provided in Table 1 . With regard to the risk group, 7% of the patients belonged to the good risk group, 63% to the intermediate risk group and 28% to the poor risk group. Mean percentage of sorted CD34 þ cells within the AML-MNC fractions was 28.9% (ranging 1-90%).
Transcriptome differences among AML CD34
þ and CD34
À cell populations versus normal BM CD34 þ cells
Unsupervised hierarchical clustering analysis using all B48 000 probe sets of CD34 þ AML and CD34 À AML, as well as CD34 þ normal BM samples showed that CD34 þ normal BM samples belonged to a distinct cluster, indicating that transcriptome differences between AML and normal BM samples are relatively large, irrespective of the AML CD34 population status (Figure 1a) . Within the AML group not all paired CD34 þ and CD34
À samples clustered together. In 61% of the cases (27/44 AMLs) the CD34 þ transcriptome did not cluster together with the paired CD34 À transcriptome, whereas in 39% of the cases (17/44 AMLs) the CD34 þ and CD34 À transcriptomes did cluster together (Figure 1a) . Thus, these data indicate that in the majority of AML cases the leukemic stem cell-enriched CD34 þ gene expression profile is quite distinct from the leukemic CD34 À compartment. Between these two groups, no differences were observed regarding CD34% (P ¼ 0.21, Mann-Whitney U), frequency of NPMc þ (P ¼ 0.28, Fisher exact) and FLT3-ITD (P ¼ 0.99, Fisher exact), age at diagnosis (P ¼ 0.38, MannWhitney U) and cytogenetic risk group (P ¼ 0.40, w 2 -test). The difference in clustering was also not related to a difference in contamination of lymphoid cells. FACS analysis of the AML-MNC fraction revealed no significant differences in the mean percentages of CD3 þ (3.9 versus 4.3%, P ¼ 0.54) and CD19 þ (5.6 versus 4.6%, P ¼ 0.81, Mann-Whitney U) cells between AML-MNC fractions of which the CD34 þ and CD34 À cell populations did or did not cluster together. We also analyzed the correlation between clustering of the paired CD34 þ and CD34
À AML transcriptomes and the tissue source (either PB or BM). No significant correlation between these two (P ¼ 0.80) was found. To further investigate a possible effect of tissue source on the clustering of the samples, we performed microarray analyses of paired PB and BM samples from five additional AML patient samples. For this analysis the PB and BM AML samples were derived from the same patients. An unsupervised clustering analysis of these samples shows that the paired samples from one patient cluster together ( Supplementary  Figure 1) , indicating that gene expression patterns are more different between AML samples than between PB and BM within one patient.
A significant difference in blast percentages of the AML samples of which the paired CD34 þ and CD34 À transcriptomes clustered together (median percentage of blasts 80% (12-98%)) versus those of which the paired CD34 þ and CD34 À transcriptomes did not cluster together (median percentage of blasts 54% (13-96%)) was found (P ¼ 0.045). However, importantly, when the AML CD34 þ samples were divided into two groups separated based on the median blast percentage, no statistically significant differences in gene expression were found between samples with a high pre-sorting blast percentage and those with a low pre-sorting blast percentage.
Differentially expressed probe sets were identified of AML samples of which the CD34 þ and CD34 À cell populations clustered together (n ¼ 27, resulting in 136 genes) versus AML samples of which the CD34 þ and CD34 À cell populations did not cluster together (n ¼ 17, resulting in 2380 genes), and these differentially expressed gene sets were compared in a VENN diagram (Figure1b and Supplementary Tables 1 and 2 ). Regardless of whether or not CD34 þ and CD34 À transcriptomes clustered together, gene ontology analysis revealed that common differences in gene expression between CD34 þ and CD34
À groups in all AML cases (123 genes) were particularly enriched for genes that associated with T-cells and erythropoiesis ( Figure 1c ). As expected, CD34 was the highest differentially expressed gene in this subset (Supplementary  Tables 1 and 2 ). Indeed, this indicates that genes that associate with a more committed phenotype particularly specify differences between CD34 þ and CD34 À compartments, but this is the case in all AML samples and not just in those samples where CD34 þ and CD34 À transcriptomes did not cluster together. Moreover, gene expression differences between AML CD34 þ and CD34
À transcriptomes associated with differentiation programs are found in both samples with a high pre-sorting blast percentage, as well as those with a low pre-sorting blast percentage (Supplementary Figure 2) . This strongly suggests that the identified differences between CD34 þ and CD34 À AML cells associated with differentiation are not just a reflection of a difference in pre-sorting blast percentages of the AML samples.
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þ cells HJM de Jonge et al Table 4 ). In all, 2132 genes were overlapping between both analyses, and thus differentially expressed between AML and normal BM irrespective of CD34 status (hereafter referred to as common AML specific genes). A total of 1677 genes were specifically expressed in the AML CD34 þ group versus normal CD34 þ , of which 1013 were significantly higher expressed in CD34
þ AML cells compared with normal BM cells (Figure 2a) . Figure 2b shows examples of gene ontologies representing the differentially expressed genes between AML CD34 þ versus normal CD34 þ cells, AML CD34
À versus normal CD34 þ cells, as well as the common AML specific genes. A hierarchical clustering analysis using only the top 50 of AML CD34 þ specific genes is shown in Figure 2c . Of note, this top 50 list of genes is adjusted by selecting only those genes that were also present on the gene expression arrays of the validation cohorts.
By comparing the AML CD34 þ specific UP signature (1013 genes) with the list of genes differentially expressed between AML CD34 þ and CD34 À transcriptomes in all AML samples (123 genes) an overlap of 12 genes (ZMYM3, GUCY1A3, C15ORF17, TARBP1, SRBD1, LOC149134, TFPI, SUPT3H, MAP2K5, PAQR7, LOC727935, ZBTB8 and C14ORF159) was found.
Prognostic value of top 50 AML CD34
þ specific genes in normal karyotype AML Next, we wondered whether the set of 50 CD34 þ specific AML genes had prognostic significance. Therefore, univariate cox regression analyses were performed between the continuous transcript levels of these 50 CD34 þ specific genes and OS in a large series of de novo normal karyotype AMLs 36 (n ¼ 163) (Supplementary Table 5 summarizes the results for all 50 genes). These analyses revealed that 6 genes out of these 50 had predictive significance at a P-value p0.01, whereby higher expression levels correlated with poor survival rates.
Next, these findings were validated in an independent cohort of 218 normal karyotype AMLs 6 (Supplementary Table 5 ). Interestingly, higher transcript levels of three of the 50 CD34 þ AML specific genes (that is, ANKRD28, GNA15 and UGP2) were associated with a significant poorer OS in both cohorts of normal karyotype AML at the significance of Po0.01 (Supplementary Table 5 ). For the cohort of 218 normal karyotype AMLs also EFS data were available for further analyses. A significant association between the continuous transcript levels of ANKRD28, GNA15 and UGP2 with unfavorable EFS was evident (ANKRD28: hazard ratio (HR): 1.30, 95% CI: 1.07-1.56, P ¼ 0.007; GNA15: HR: 1.23, 95% CI: 1.05-1.45, P ¼ 0.012; and UGP2: HR: 2.04, 95% CI: 1.34-3.11, P ¼ 0.001). Subsequently, these three genes were summed and divided in tertiles (low, intermediate and high expression). As expected, higher transcript levels of these three genes were strongly associated with poorer OS and EFS in the cohort of 218 normal karyotype AMLs (Figures 3a and b , P ¼ 0.007 and P ¼ 0.006, respectively). Also in the independent cohort of 163 normal karyotype AMLs, Kaplan-Meier curves showed that patients with high expression levels of these three genes had a significantly worse OS compared with patients with low expression levels (Figure 3c, Po0.001 ). Of note, we also analyzed the prognostic relevance of the sum of expression of the top 50 AML CD34 þ specific genes. Univariate cox regression analyses revealed that higher transcript levels of the sum of these 50 genes were associated with poorer outcome (Metzeler dataset Prognostic value of ANKRD28, GNA15 and UGP2 and the sum expression level in the context of known disease-related risk factors
Well-known disease-related risk factors such as FLT3-ITD, NPM1c þ and CEBPA mutation status, and white blood cell count were considered in a multivariate analysis in the cohort of 218 normal karyotype AMLs for both OS (ANKRD28: HR: 1.32, 95% CI: 1.07-1.62, P ¼ 0.008; GNA15: HR: 1.22, 95% CI: 1.02-1.47, P ¼ 0.033; UGP2: HR: 1.86, 95% CI: 1.17-2.97, P ¼ 0.009 and sum expression: HR: 1.20, 95% CI 1.08-1.33, P ¼ 0.001), as well as EFS (ANKRD28: HR: 1.31, 95% CI: 1.09-1.59, P ¼ 0.005; GNA15: HR: 1.21, 95% CI: 1.02-1.43, P ¼ 0.030; UGP2: HR: 1.73, 95% CI: 1.11-2.68, P ¼ 0.015; and sum expression: HR: 1.17, 95% CI 1.07-1.29, P ¼ 0.001) (details in Table 2 ). These data indicate that the continuous transcript levels of ANKRD28, GNA15 and UGP2 when analyzed as individual genes, as well as the sum of these three genes are independent risk indicators for both OS and EFS.
Discussion
In recent years, major advances have been achieved in predicting the outcome of newly diagnosed AML patients. However, there is still need for more powerful and independent prognostic factors that can guide treatment decisions, especially for the large subgroup of patients presenting with normal karyotype AML. In the present study, GEP was performed on purified CD34
þ AML cells and the results were compared with normal CD34 þ cells. This allowed the identification of a top 50 list of genes that were differentially expressed in AML CD34 þ versus normal CD34 þ cells, and versus AML CD34 À cells. Interestingly, for three of these genes (ANKRD28, GNA15 and UGP2) a high transcript level was associated with a significant poorer OS in normal karyotype AML patients, as validated in two independent cohorts of normal karyotype AML patients. Importantly, the prognostic value of the continuous transcript levels of ANKRD28, GNA15 and UGP2 was shown to be independent from the well-known risk factors FLT3-ITD, NPM1c þ and CEBPA mutation status. Genome-wide GEP techniques have been applied to derive prognostic signatures for AML that would identify subsets of patients with certain outcomes. In normal karyotype AML patients, Bullinger et al. distinguished two different prognostically relevant clusters using 133 probe sets. 7 More recently, þ -specific genes as shown in Supplementary Table 5 .
Gene expression profiling in AML CD34 þ cells HJM de Jonge et al an additional study in normal karyotype AML identified a gene signature of 86 probe sets correlating significantly with OS in 163 patients. This was validated and confirmed in an independent cohort of 79 normal karyotype AML patients. 36 A limitation in applying these results to clinical practice is the number of genes that have to be studied. By using the more purified AML CD34 þ population and a large cohort of normal BM samples, we were able to identify a small gene set with strong prognostic significance. A single PCR measurement of these three genes can be easily incorporated in routine diagnostic measurements.
To place the results of our study in the perspective of previous findings, we compared our list of top 50 AML CD34 þ specific genes with previously identified prognostically relevant AML gene signatures. Importantly to note, our three identified target genes are not included in the previously described prognostically relevant sets of 133 genes 7 and 86 genes. 36 Even when considering all top 50 AML CD34 þ specific genes, only one gene was found to overlap with one of the previously identified prognostic signatures. FLT3 was identified previously by Bullinger et al. 7 and is the first gene in our list of AML CD34 þ specific genes, suggesting that upregulation of FLT3 might be important in the biology of AML. Although almost no overlap was seen, the different identified signatures might nevertheless reflect the same underlying biology. Underestimation of the overlap in gene expression patterns cannot be excluded as different studies used different array platforms and filtered datasets were used for the comparisons.
Very recently, also Gentles et al. 38 defined a leukemic stem cell gene expression signature and found this signature to be strongly associated with clinical outcome in AML. The LSC signature identified by Gentles et al. was shown to be highly expressed not only in leukemic, but also in normal hematopoietic stem cells. One could hypothesize that particularly those genes that are differentially expressed between leukemic and normal stem cells are of interest in the perspective of the biology of leukemia and also for prognosis and therapy. Indeed, while our top 50 AML CD34 þ specific gene signature shows prognostic relevance, the signature of genes differentially expressed between AML CD34 þ and CD34
À irrespective of clustering of the CD34 þ and CD34 À transcriptomes (123 genes) is not associated with clinical outcome. These data strongly suggest the importance of comparing leukemic CD34 þ transcriptomes with its normal counterpart. The importance of sorting the CD34 þ AML population was reflected by the observation that survival could not be predicted by the top 50 of AML CD34 À specific genes. Gene ontology analysis of the differentially expressed genes between AML CD34 þ and CD34 À revealed biological Gene expression profiling in AML CD34 þ cells HJM de Jonge et al processes involved in differentiation and apoptosis. As the gene expression differences associated with differentiation do not seem to correlate with the contamination of lymphoid cells or pre-sorting blast percentages, we believe that these differences might reflect underlying biology of CD34 þ and CD34 À AML cells and are not just determined by contaminating nonleukemic cells. This is in line with the idea that although leukemic CD34
À cells appear as immature blasts, still a hierarchy of maturation might be present in leukemia. 39 Some upregulated gene ontology biological processes in CD34 þ AML versus normal BM are involved in metabolic processes, suggesting higher metabolic activity in leukemia. Future studies should be aimed at a further characterization of these pathways in leukemias, and whether targeting these might provide alternative means to eradicate leukemic stem cells.
There is only limited data on the three target genes we identified. The protein encoded by ANKRD28 (also known as PITK; Phosphatase Interactor Targeting K protein) was shown to selectively bind and dephosphorylate the transcriptional regulator heterogeneous nuclear ribonucleoprotein K by targeting protein phosphatase-1. Interestingly, a gene fusion of ANKRD28 on 3p25 to NUP98 on 11p15 was described in a patient with high-risk myelodysplasia. 40 In the latter study, NIH/3T3 cells transfected with wild-type ANKRD28 showed suppressed colony formation compared with control cells, whereas the ANKRD28-NUP98 fusion-induced malignant transformation. 40 The expression of G15 a-subunit (formerly the human isoform was named G16) encoded by GNA15 seems to be restricted to immature hematopoietic and epithelial cells (reviewed in Giannone et al. 41 ). Although poorly understood, G15 a-subunit was shown to regulate cell differentiation and apoptosis through modulation of MAPKs 42 and transcription factors such as NF-kB, 43 and is capable of activating STAT3. 44 Interestingly, the expression of the third target gene UGP2 was recently shown to be upregulated by hypoxia in hepatocytes. 45 UGP2 was put forward as a potential target of hypoxia-inducible factors, which in turn are required for hematopoiesis 46, 47 and hypothesized to be relevant in hematopoietic stem cell maintenance in hypoxic osteoblastic BM niches. Further studies are needed to elucidate specific roles of UGP2, as well as ANKRD28 and GNA15 in AML.
In conclusion, our study suggests that risk classification of normal karyotype AML might be further improved by using a selective set of genes, which are highly expressed in the leukemic stem cell-enriched CD34 þ cell fraction.
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